ArticleFrontiers in oncology2022

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.

Nur Olgun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.